<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31820274</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>06</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1878-7479</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title>
          <ISOAbbreviation>Neurotherapeutics</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial.</ArticleTitle>
        <Pagination>
          <StartPage>704</StartPage>
          <EndPage>709</EndPage>
          <MedlinePgn>704-709</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-019-00813-5</ELocationID>
        <Abstract>
          <AbstractText>This was a substudy of a randomized, double-blind, placebo-controlled trial originally designed to explore the effect of dalfampridine on information processing speed (2013-002558-64 EU Clinical Trials Register) in patients with multiple sclerosis (MS). A total of 120 patients were originally randomized in a 2:1 ratio to receive dalfampridine 10 mg or placebo twice daily for 12 weeks. Here, we sought to explore the effect of dalfampridine on static balance in single-task and dual-task conditions in a subgroup of 41 patients. They underwent static posturography in quiet standing (single-task) and while performing the Stroop test (dual-task) at randomization (baseline), after 12 weeks and after a 4-week wash-out period. Baseline characteristics of active group (n = 27) did not differ from those of placebo group (n = 14). Dalfampridine treatment was associated with better balance control than placebo in both single-task (F = 4.80, p = 0.034) and dual-task (F = 6.42, p = 0.015) conditions, with small-to-moderate effect sizes (Cohen's f<sup>2</sup> = 0.122-0.162). The beneficial effect of dalfampridine was not retained 4 weeks after its discontinuation. The rate of accidental falls per month did not differ between the two groups (p = 0.12). Our preliminary findings suggest that dalfampridine can be considered a potential option to treat balance impairment due to MS. Larger sample sizes are needed to verify if the beneficial effect of dalfampridine on balance can be translated into a reduced risk of accidental falls.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Prosperini</LastName>
            <ForeName>Luca</ForeName>
            <Initials>L</Initials>
            <Identifier Source="ORCID">0000-0003-3237-6267</Identifier>
            <AffiliationInfo>
              <Affiliation>Dept. of Neurosciences, S. Camillo-Forlanini Hospital, C.ne Gianicolense 87, 00152, Rome, Italy. luca.prosperini@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Castelli</LastName>
            <ForeName>Letizia</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS) Fondazione Don Carlo Gnocchi, -, Piazzale Morandi 6, 20121, Milano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Giglio</LastName>
            <ForeName>Laura</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Neurology Unit, S. Filippo Neri Hospital, Via G. Martinotti 20, 00135, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>S. Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bonanno</LastName>
            <ForeName>Valeria</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>S. Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Dept. of Human Neuroscience, Sapienza University, Viale dell'Università 30, 00185, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gasperini</LastName>
            <ForeName>Claudio</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Dept. of Neurosciences, S. Camillo-Forlanini Hospital, C.ne Gianicolense 87, 00152, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pozzilli</LastName>
            <ForeName>Carlo</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>S. Andrea Hospital, Sapienza University, Via di Grottarossa 1035, 00189, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Dept. of Human Neuroscience, Sapienza University, Viale dell'Università 30, 00185, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>EudraCT</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>2013-002558-64</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Neurotherapeutics</MedlineTA>
        <NlmUniqueID>101290381</NlmUniqueID>
        <ISSNLinking>1878-7479</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D026902">Potassium Channel Blockers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>BH3B64OKL9</RegistryNumber>
          <NameOfSubstance UI="D015761">4-Aminopyridine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015761" MajorTopicYN="N">4-Aminopyridine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004856" MajorTopicYN="N">Postural Balance</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D026902" MajorTopicYN="N">Potassium Channel Blockers</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Multiple sclerosis</Keyword>
        <Keyword MajorTopicYN="Y">accidental falls</Keyword>
        <Keyword MajorTopicYN="Y">balance</Keyword>
        <Keyword MajorTopicYN="Y">clinical trial</Keyword>
        <Keyword MajorTopicYN="Y">dalfampridine</Keyword>
      </KeywordList>
      <CoiStatement>LP: consulting and lecture fees and travel grants from Almirall, Biogen, Novartis, Genzyme, Roche, and Teva; and research funding from Associazione Italiana Sclerosi Multipla and Genzyme. LC: consulting fees from Almirall. LDG: travel grants from Biogen, Genzyme, Teva, and Novartis; consulting fees from Genzyme, Merck, Novartis, and Biogen. VB: nothing to disclose. CG: consulting fees from Bayer and Biogen, and lecture fees from Biogen, Bayer, Genzyme, Merck, Novartis, and Teva. CP: consulting and lecture fees and research funding and travel grants from Almirall, Actelion, Bayer, Biogen, Genzyme, Merck, Novartis, Roche, and Teva.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>11</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31820274</ArticleId>
        <ArticleId IdType="pmc">PMC7283428</ArticleId>
        <ArticleId IdType="doi">10.1007/s13311-019-00813-5</ArticleId>
        <ArticleId IdType="pii">10.1007/s13311-019-00813-5</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>De Giglio L, De Luca F, Gurreri F, et al. Effect of dalfampridine on information processing speed impairment in multiple sclerosis. Neurology. 2019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31331968</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amato MP, Portaccio E, Goretti B, et al.  The Rao’s Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler. 2006;12:787–793. doi: 10.1177/1352458506070933.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458506070933</ArticleId>
            <ArticleId IdType="pubmed">17263008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leone C, Patti F, Feys P. Measuring the cost of cognitive-motor dual tasking during walking in multiple sclerosis. Mult. Scler. 2015;21(2):123–131. doi: 10.1177/1352458514547408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458514547408</ArticleId>
            <ArticleId IdType="pubmed">25178543</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leone C, Feys P, Moumdjian L, et al.  Cognitive-motor dual-task interference: a systematic review of neural correlates. Neurosci. Biobehav. Rev. 2017;75:348–360. doi: 10.1016/j.neubiorev.2017.01.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neubiorev.2017.01.010</ArticleId>
            <ArticleId IdType="pubmed">28104413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prosperini L, Castelli L, De Luca F, et al.  Task-dependent deterioration of balance underpinning cognitive-postural interference in MS. Neurology. 2016;87(11):1085–1092. doi: 10.1212/WNL.0000000000003090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003090</ArticleId>
            <ArticleId IdType="pubmed">27521436</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalron A, Allali G, Achiron A. Cerebellum and cognition in multiple sclerosis: the fall status matters. J Neurol. 2018;265:809–816. doi: 10.1007/s00415-018-8774-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-018-8774-2</ArticleId>
            <ArticleId IdType="pubmed">29396679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalron A. The relationship between specific cognitive domains, fear of falling, and falls in people with multiple sclerosis. Biomed Res Int. 2014;2014:281760. doi: 10.1155/2014/281760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2014/281760</ArticleId>
            <ArticleId IdType="pmc">PMC4131562</ArticleId>
            <ArticleId IdType="pubmed">25165694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prosperini L, Sbardella E, Raz E, et al.  Multiple sclerosis: white and gray matter damage associated with balance deficit detected at static posturography. Radiology. 2013;268(1):181–189. doi: 10.1148/radiol.13121695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1148/radiol.13121695</ArticleId>
            <ArticleId IdType="pubmed">23533287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruggieri S, Fanelli F, Castelli L, et al.  Lesion symptom map of cognitive-postural interference in multiple sclerosis. Mult Scler. 2018;24:653–662. doi: 10.1177/1352458517701313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458517701313</ArticleId>
            <ArticleId IdType="pmc">PMC5946662</ArticleId>
            <ArticleId IdType="pubmed">28337941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fjeldstad C, Suárez G, Klingler M, et al.  Dalfampridine effects beyond walking speed in multiple sclerosis. Int. J. MS Care. 2015;17(6):275–283. doi: 10.7224/1537-2073.2014-036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7224/1537-2073.2014-036</ArticleId>
            <ArticleId IdType="pmc">PMC4673920</ArticleId>
            <ArticleId IdType="pubmed">26664333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hupperts R, Lycke J, Short C, et al.  Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial. Mult. Scler. 2016;22(2):212–221. doi: 10.1177/1352458515581436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458515581436</ArticleId>
            <ArticleId IdType="pmc">PMC4749757</ArticleId>
            <ArticleId IdType="pubmed">25921050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filli L, Zorner B, Kapitza S, et al.  Monitoring long-term efficacy of fampridine in gait impaired patients with multiple sclerosis. Neurology. 2017;88:832–841. doi: 10.1212/WNL.0000000000003656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000003656</ArticleId>
            <ArticleId IdType="pubmed">28148629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albrecht P, Bjorna IK, Brassat D, et al. Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. Ther Adv Neurol Disord. 2018; 11: doi:10.1177/1756286418803248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6174649</ArticleId>
            <ArticleId IdType="pubmed">30305850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thompson AJ, Banwell BL, Barkhof F, et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173. doi: 10.1016/S1474-4422(17)30470-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(17)30470-2</ArticleId>
            <ArticleId IdType="pubmed">29275977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lublin FD, Reingold SC, Cohen JA, et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–286. doi: 10.1212/WNL.0000000000000560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000000560</ArticleId>
            <ArticleId IdType="pmc">PMC4117366</ArticleId>
            <ArticleId IdType="pubmed">24871874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67:588–597. doi: 10.1207/s15327752jpa6703_13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1207/s15327752jpa6703_13</ArticleId>
            <ArticleId IdType="pubmed">8991972</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS) Neurology. 1983;33:1444–1452. doi: 10.1212/WNL.33.11.1444.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.33.11.1444</ArticleId>
            <ArticleId IdType="pubmed">6685237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prosperini L, Fortuna D, Giannì C, Leonardi L, Pozzilli C. The diagnostic accuracy of static posturography in predicting accidental falls in people with multiple sclerosis. Neurorehabil Neural Repair. 2013;27:45–52. doi: 10.1177/1545968312445638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1545968312445638</ArticleId>
            <ArticleId IdType="pubmed">22593115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wajda DA, Motl RW, Sosnoff JJ. Three-month test-retest reliability of center of pressure motion during standing balance in individuals with multiple sclerosis. Int J MS Care. 2016;18:59–62. doi: 10.7224/1537-2073.2015-014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7224/1537-2073.2015-014</ArticleId>
            <ArticleId IdType="pmc">PMC4849397</ArticleId>
            <ArticleId IdType="pubmed">27134578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melillo F, Di Sapio A, Martire S, Malentacchi M, Matta M, Bertolotto A. Computerized posturography is more sensitive than clinical Romberg test in detecting postural control impairment in minimally impaired multiple sclerosis patients. Mult Scler Relat Disord. 2017;14:51–55. doi: 10.1016/j.msard.2017.03.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2017.03.008</ArticleId>
            <ArticleId IdType="pubmed">28619432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cattaneo D, Jonsdottir J. Sensory impairments in quiet standing in subjects with multiple sclerosis. Mult Scler. 2009;15:59–67. doi: 10.1177/1352458508096874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458508096874</ArticleId>
            <ArticleId IdType="pubmed">18845654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalron A, Nitzani D, Achiron A. Static posturography across the EDSS scale in people with multiple sclerosis: a cross sectional study. BMC Neurol. 2016;16:70. doi: 10.1186/s12883-016-0603-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12883-016-0603-6</ArticleId>
            <ArticleId IdType="pmc">PMC4873986</ArticleId>
            <ArticleId IdType="pubmed">27206921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalron A, Givon U, Frid L, Dolev M, Achiron A. Static posturography and falls according to pyramidal, sensory and cerebellar functional systems in people with multiple sclerosis. PLoS One. 2016;11:e0164467. doi: 10.1371/journal.pone.0164467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0164467</ArticleId>
            <ArticleId IdType="pmc">PMC5065137</ArticleId>
            <ArticleId IdType="pubmed">27741268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhuang Y, Guan Y, Qiu L, et al.  A novel rank-based non-parametric method for longitudinal ordinal data. Stat. Methods Med. Res. 2018;27(9):2775–2794. doi: 10.1177/0962280216686628.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0962280216686628</ArticleId>
            <ArticleId IdType="pubmed">28067124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Benedict RHB, DeLuca J, Phillips G, et al.  Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23:721–733. doi: 10.1177/1352458517690821.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458517690821</ArticleId>
            <ArticleId IdType="pmc">PMC5405816</ArticleId>
            <ArticleId IdType="pubmed">28206827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giannì C, Prosperini L, Jonsdottir J, Cattaneo D. A systematic review of factors associated with accidental falls in people with multiple sclerosis: a meta-analytic approach. Clin Rehabil. 2014;28:704–16. doi: 10.1177/0269215513517575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0269215513517575</ArticleId>
            <ArticleId IdType="pubmed">24569653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Claassen J, Spiegel R, Kalla R, et al.  A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptoms. J Neurol Neurosurg Psychiatry. 2013;84:1392–1399. doi: 10.1136/jnnp-2012-304736.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2012-304736</ArticleId>
            <ArticleId IdType="pubmed">23813743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horton L, Conger A, Conger D, et al.  Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy. Neurology. 2013;80:1862–1866. doi: 10.1212/WNL.0b013e3182929fd5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182929fd5</ArticleId>
            <ArticleId IdType="pmc">PMC3908347</ArticleId>
            <ArticleId IdType="pubmed">23616154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prosperini L, Leonardi L, De Carli P, Mannocchi ML, Pozzilli C. Visuo-proprioceptive training reduces risk of falls in patients with multiple sclerosis. Mult Scler. 2010;16:491–499. doi: 10.1177/1352458509359923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458509359923</ArticleId>
            <ArticleId IdType="pubmed">20150396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalla R, Teufel J, Feil K, Muth C, Strupp M. Update on the pharmacotherapy of cerebellar and central vestibular disorders. J. Neurol. 2016;263(Suppl 1):S24–29. doi: 10.1007/s00415-015-7987-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-015-7987-x</ArticleId>
            <ArticleId IdType="pmc">PMC4833819</ArticleId>
            <ArticleId IdType="pubmed">27083881</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strupp M, Kalla R, Glasauer S, et al.  Aminopyridines for the treatment of cerebellar and ocular motor disorders. Progr Brain Res. 2008;171:535–541. doi: 10.1016/S0079-6123(08)00676-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0079-6123(08)00676-6</ArticleId>
            <ArticleId IdType="pubmed">18718350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schniepp R, Jakl V, Wuehr M, et al.  Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report. Mult Scler. 2012;19:506–508. doi: 10.1177/1352458512461394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458512461394</ArticleId>
            <ArticleId IdType="pubmed">23069878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt S. Fampridine improves severe dysarthria in secondary-progressive multiple sclerosis. Mult Scler. 2013;19:511. doi: 10.1177/1352458512458554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1352458512458554</ArticleId>
            <ArticleId IdType="pubmed">22936332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galea MP, Cofré Lizama LE, Butzkueven H, Kilpatrick TJ. Gait and balance deterioration over a 12-month period in multiple sclerosis patients with EDSS scores ≤3.0. NeuroRehabilitation. 2017;40:277–284. doi: 10.3233/NRE-161413.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3233/NRE-161413</ArticleId>
            <ArticleId IdType="pubmed">28222549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filli L, Sutter T, Easthope CS, et al.  Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time. Sci Rep. 2018;8:4984. doi: 10.1038/s41598-018-22676-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-22676-0</ArticleId>
            <ArticleId IdType="pmc">PMC5862880</ArticleId>
            <ArticleId IdType="pubmed">29563533</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
